Clinical Trial Update: GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence [Phase 3]

View source ↗

Summary

Phase 3 trial evaluated valsartan, an angiotensin II AT1-receptor blocker, for preventing recurrence of atrial fibrillation. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• VALSARTAN (Valsartan)

Snippet

Sponsor: Gruppo di Ricerca GISSI | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED